Pharmacotherapy for hyponatremia in heart failure:: Effects of a new dual V1A/V2 vasopressin antagonist YM087

被引：0
|
作者：
Abraham, WT
Suresh, DP
Wagoner, LE
Haas, GJ
McCord, J
Rydzinski, S
Nelson, CB
Bakker-Arkema, RG
机构：
[1] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] Parke Davis Pharm Res, Ann Arbor, MI USA
来源：
CIRCULATION | 1999年 / 100卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1562
引用
收藏
页码：299 / 299
页数：1
相关论文
共 50 条
  • [31] Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure
    Veeraveedu, Punniyakoti T.
    Watanabe, Kenichi
    Ma, Meilei
    Palaniyandi, Suresh S.
    Yamaguchi, Ken'ichi
    Suzuki, Kenji
    Kodama, Makoto
    Aizawa, Yoshifusa
    BIOCHEMICAL PHARMACOLOGY, 2007, 74 (10) : 1466 - 1475
  • [32] A novel oral vasopressin V2 receptor antagonist for the treatment of acute decompensated heart failure and hyponatremia
    Jennings, Douglas L.
    Kalus, James S.
    FORMULARY, 2008, 43 (07) : 236 - +
  • [33] A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
    Wada, Koh-ichi
    Matsuyawa, Utane
    Fujimori, Akira
    Arai, Yukinori
    Sudoh, Katsumi
    Sasamata, Masao
    Miyata, Keiji
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2007, 30 (01) : 91 - 95
  • [34] Vascular Effects of RWJ-676070, a Selective Combined V1a/V2 Vasopressin Receptor Antagonist
    Coltamai, L.
    Bucher, M.
    Maillard, M. P.
    Shukla, U.
    Bohidar, N.
    Haskell, L.
    Bertelsen, K.
    Fedgchin, M.
    Vogt, B.
    Burnier, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (02) : 145 - 148
  • [35] Novel vasopressin V1A and V2 antagonist (Conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia
    Verbalis, JG
    Bisaha, JG
    Smith, N
    CIRCULATION, 2004, 110 (17) : 723 - 723
  • [36] Novel vasopressin V1A and V2 antagonist (conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia
    Verbalis, JG
    Bisaha, JG
    Smith, N
    JOURNAL OF CARDIAC FAILURE, 2004, 10 (04) : S27 - S27
  • [37] Mapping peptide antagonist binding sites of the human V1a and V2 vasopressin receptors
    Mouillac, B
    Phalipou, S
    Cotte, N
    Balestre, MN
    Hibert, M
    Manning, M
    Barberis, C
    VASOPRESSIN AND OXYTOCIN: MOLECULAR, CELLULAR, AND CLINICAL ADVANCES, 1998, 449 : 359 - 361
  • [38] Chronic vasopressin V1A but not V2 receptor antagonism prevents heart failure in chronically infarcted rats
    Van Kerckhoven, R
    Lankhuizen, I
    van Veghel, R
    Saxena, PR
    Schoemaker, RG
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 449 (1-2) : 135 - 141
  • [39] Acute and chronic administration of YM087, a nonpeptide vasopressin antagonist, in rats with high-output heart failure.
    Tomura, Y
    Yatsu, T
    Uchida, W
    Inagaki, O
    Tanaka, A
    Tomioka, K
    Yanagisawa, I
    Toichi, T
    CIRCULATION, 1996, 94 (08) : 1544 - 1544
  • [40] Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?
    Greenberg, Arthur
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (06) : 904 - 907
12345